Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Anti-Epidermal Growth Factor Receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Sheep anti-EGFR antibody was used to detect EGFR by immunofluorescence in mouse oocyte cumulus cells that were previously fixed in 4% paraformaldehyde. Sheep anti-epidermal growth factor receptor (EGFR) can be used for immunohistochemistry, immunoprecipitation, western blot and immunocytochemistry applications.
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
ActiveUS9266960B2Peptide/protein ingredientsAntibody mimetics/scaffoldsAntigen receptorsAntigen binding
The disclosure provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
Owner:UNITED STATES OF AMERICA
Humanised antibodies to epidermal growth factor receptor
InactiveCN1432063AOrganic active ingredientsFungiHuman epidermal growth factor receptorMurine antibody
The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer.
Owner:SCANCELL
Human anti-epidermal growth factor receptor single-chain antibodies
InactiveUS7045127B2Radioactive preparation carriersImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenSingle-Chain Antibodies
Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal growth factor receptor and the truncated and / or mutated epidermal growth factor receptor on human cells. These anti-EGFR-scFvs are useful as therapeutic and / or diagnostic agents.
Owner:UAB RES FOUND
Vitamin k for prevention and treatment of skin rash secondary to Anti-egfr therapy
InactiveUS20090239952A1Effective treatmentPrevent skinBiocideDigestive systemSerum rashPhosphatase inhibitor
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Recombinant monoclonal antibody against EGFR
ActiveCN1827647AHigh affinityHigh expressionImmunoglobulins against animals/humansFermentationHeavy chainMonoclonal antibody
The invention provides a monoclonal antibody of human source anti-epidermal growth factor receptor comprising heavy-chain variable area with amino acid sequence displayed by SEQ ID NO three and light-chain variable area with amino acid sequence displayed by SEQ ID NO four. The invention also provides methods for preparation of DNA molecule used for coding the said amino acid sequence, expression carrier which comprises the said DNA molecules, host cell and antibody, the usage and drug composition comprising the said antibody.
Owner:SHANGHAI ZHANGJIANG BIOTECH
Antibody cocktails for breast cancer radioimmunotherapy
InactiveUS20150030534A1Radioactive preparation carriersRadiation therapyAntigen bindingImmune therapy
The present invention provides compositions comprising a therapeutically effective combination of at least two of radionuclide-labeled anti-Epidermal Growth Factor Receptor (anti-EGFR), radionuclide-labeled anti-CD-44, and radionuclide-labeled anti-CD-73. or their respective antigen binding portions, and a pharmaceutically acceptable carrier, and method of use thereof for the treatment of breast cancer.
Owner:RUTGERS THE STATE UNIV
Antibody, and coding gene and application thereof
The invention discloses an antibody, and a coding gene and application thereof. An amino acid sequence of a heavy chain variable region of the antibody is shown in the sequence 2 in a sequence table, while the amino acid sequence of a light chain is shown in the sequence 3 in the sequence table. Experimental results prove that the antibody of the invention has high binding activity (affinity is 2.7*10-8 mol / L) and high tumor cell growth and migration suppression capacity; and the affinity of an anti-epidermal growth factor receptor (EGFR) human-mouse chimeric antibody Cetuximab in foreign markets is 1.1*10-9 M. The humanized antibody of the invention can be better bound with an EGFR so as to ensure anti-tumor effect thereof. An anti-body preparation method of the invention has the advantage of simultaneously expressing the light chain and the heavy chain variable region. After all, the antibody and the preparation method thereof have vast application prospect in the field of the prevention and / or treatment of tumors.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Human anti-epidermal growth factor receptor single-chain antibodies
InactiveUS20060110324A1Hybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenSingle-Chain Antibodies
Owner:UAB RES FOUND
Novel anti-epidermal growth factor receptor antibody, preparation method and application thereof
InactiveCN104910275AImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsBinding siteEGFR Antibody
The invention discloses a novel anti-epidermal growth factor receptor EGFR antibody, a preparation method and application thereof. The novel whole human source anti-EGFR monoclonal antibody Pan-P provided by the invention is IgG1 type antibody, and has ADCC effect. Also, the antigen-binding site of the antibody provided by the invention contains a section of blocking peptide with tumor-specific protease cleavage site. The antibody is an enzyme-mediated specific binding antibody, has specific binding effect to tumors, and can reduce skin toxicity caused by general anti-EGFR antibodies.
Owner:TAIZHOU MABTECH PHARM CO LTD
Anti-epidermal growth factor receptor antibodies and uses thereof
InactiveUS20130022624A1High affinityHigh binding activityOrganic active ingredientsSugar derivativesHuman epidermal growth factor receptorEpidermal Growth Factor Receptor Antibody
The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10−10 mol / L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
Owner:GUANGZHOU YUNYUAN BIOTECH
Preparation method of novel cytokine fusion protein IP10 single-chain antibody
InactiveCN103451218AEnhance targeted killing activityImprove targetingMicroorganism based processesIn-vivo testing preparationsEscherichia coliPhage antibodies
The invention discloses a preparation method of a novel cytokine fusion protein-chemokine interferon inducible protein 10 single-chain antibody (IP10-scFv). The method comprises the steps of: S1. synthesizing a human IP10 extracellular terminal gene; S2. utilizing a recombinant phage antibody system to construct the single-chain antibody of an anti-epidermal growth factor receptor mutant III (EGFRvIII); S3. conducting optimization synthesis on a (Gly4Ser)3 flexible joint; S4. cloning IP10 and the anti-EGFRvIII single-chain antibody into an eukaryotic expression vector, and conducting connection through the optimized (Gly4Ser)3 flexible joint, thus obtaining an IP10-scFv gene; and S5. subjecting the gene to high expression in Escherichia coli, thus obtaining IP10-scFv with biological activity. The IP10-scFv provided in the invention has a higher antigen-antibody binding rate, can reduce the dosage of IP10 clinically and reduce the toxic and side effects, and further can reduce the adoptive input amount of glioma specific cytotoxic T lymphocyte (CTL) and increase the activity of CTL.
Owner:卢小玲 +1
Fully human anti-epidermal growth factor receptor antibodies
ActiveUS8071093B1Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsNucleic acid sequencingEpidermal Growth Factor Receptor Antibody
Owner:SAMSUNG ELECTRONICS CO LTD
Anti-epidermal growth factor receptor antibodies and uses thereof
InactiveUS8486895B2High affinityHigh binding activitySugar derivativesPeptide/protein ingredientsEpidermal Growth Factor Receptor AntibodyTumor cells
The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10−10 mol / L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
Owner:GUANGZHOU YUNYUAN BIOTECH
Application of monoclonal antibody in treating esophageal cancer
Relating to the field of medicines, the invention specifically relates to application of a monoclonal antibody resisting an epidermal growth factor receptor (EGFR) in treating esophageal cancer, especially a humanized monoclonal antibody, nimotuzumab. The monoclonal antibody is a specifically purified antibody generated for specific antigens. With high specificity, the monoclonal antibody can be used for targeted therapy specifically to tumor cells, and can reverse malignant biological behaviors of tumor cells at a molecular level. Characterized by strong targeting, high specificity and low toxic as well as side effect, etc., the monoclonal antibody provided in the invention can substantially strengthen the curative effects of radiotherapy and chemotherapy.
Owner:BIOTECH PHARMA CO LTD
Preparation method, related intermediate, and application of anti-epidermal growth factor receptor drug-resistance mutation inhibitor
ActiveCN108191849AReaction raw materials are readily availableFew reaction stepsOrganic chemistryAntineoplastic agentsSolvent2-aminothiazole
The invention provides a preparation method of an anti-epidermal growth factor receptor drug-resistance mutation inhibitor, 2-(5-fluoro-2-hydroxyphenyl)-2-(isoindoline-1-one)-N-(2-thiazolyl)acetamide(I). The method includes steps of: performing an acid catalytic reaction to isoindoline-1-one, a glyoxylic acid hydrate, and p-fluorophenol in an acidic solvent to obtain a novel intermediate compound(II): 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-2-indenyl)acetic acid; and then performing a condensation reaction with 2-aminothiazole to obtain the compound (I). The method has short reaction route, simple operation, safe processes, high yield, gentle conditions, good repeatability and low cost, is suitable for industrial production and has great application value.
Owner:SHANGHAI SUNTECH PHARMA
Anti-PD1-CD19 bispecific antibody, pharmaceutical composition thereof and application thereof
PendingCN111944051ASmall molecular weightEnhanced non-specific killingHybrid immunoglobulinsAntibody ingredientsSingle-Chain AntibodiesComplementarity determining region
The invention relates to the field of antibody drugs, and particularly relates to an anti-PD1-CD19 bispecific antibody, a pharmaceutical composition thereof and application thereof. The antibody comprises a heavy chain and a light chain, wherein the heavy chain and the light chain both comprise variable regions, and the variable regions comprise complementary determining regions. The antibody further comprises an immunoglobulin antibody IgG and a variable fragment scFv, wherein the scFv comprises a variable region VH and a variable region VL. According to the antibody, two specific single-chain antibodies are connected in series by using a molecular biological technology, one end of an anti-epidermal growth factor receptor is used for recognizing tumor cells, and the other end of the anti-epidermal growth factor receptor is used for recognizing and activating T lymphocytes by using an anti-PD1 single-chain antibody, so that the effect of removing the tumor cells is achieved.
Owner:SHUNHAO CELL BIOTECHNOLOGY (TIANJIN) CO LTD
Anti-EGFR single-chain antibody, anti-PD1 single-chain antibody and fusion protein
ActiveCN109879964AEnhanced non-specific killingReduce manufacturing costImmunoglobulins against cell receptors/antigens/surface-determinantsHybrid peptidesSingle-Chain AntibodiesAnti pd1
The invention discloses an anti-epidermal growth factor receptor single-chain antibody, an anti-PD1 single-chain antibody and a fusion protein, and an application thereof. The double-specific single-chain antibody has highly specific antigen recognition ability, not only has the specific recognition function of the antibody, but also has excellent anti-tumor effect; moreover, the antibody fusion protein has small molecular weight, can be expressed in a prokaryotic cell expression system, greatly reduces the production cost of antibody drugs, and has good clinical application prospects.
Owner:北京科立思维生物科技有限公司
Application of monoclonal antibody for treating colorectal cancer
InactiveCN102441164AAntibody ingredientsAntineoplastic agentsAntiendomysial antibodiesTherapeutic effect
The invention relates to the medicinal field, and more specifically relates to an application of a monoclonal antibody of an anti-epidermal growth factor receptor in the aspect of treating colorectal cancer, in particular to a humanized monoclonal antibody-nimotuzumab. The monoclonal antibody is a specific purified antibody generated aiming at a specific antigen, has high specificity, can specifically carry out targeted therapy aiming at tumor cells, can reverse the malignant biological behavior of the tumor cells at the molecular level, has the characteristics of strong targeting property, high specificity, low toxic side effect and the like, and can obviously enhance the therapeutic effects of radiotherapy and chemotherapy.
Owner:BIOTECH PHARMA CO LTD
Injection preparation of anti-epidermal growth factor receptor monoclonal antibody
ActiveCN107773755BImprove solubilityImprove stabilityAntipyreticAnalgesicsDiseaseAntiendomysial antibodies
The invention belongs to the field of pharmaceutical preparations, and relates to an injection preparation of a monoclonal antibody, in particular to an injection preparation of an anti-epithelial growth factor receptor (EGFR) monoclonal antibody. The present invention also relates to the use of the injection preparation for the preparation of drugs for the prevention and / or treatment of diseases related to EGFR activity disorders or disorders (such as tumors and / or tumor metastasis, diseases related to angiogenesis, non-specific inflammation) . The anti-EGFR monoclonal antibody injection preparation of the present invention exhibits good stability in tests such as shaking, 25°C and 40°C high-temperature accelerated tests, and 2-8°C long-term storage stability, and has good application prospects.
Owner:SHANGHAI JMT BIO INC
Injection preparation of epidermal growth factor receptor monoclonal antibody
ActiveCN107773755AImprove solubilityImprove stabilityAntipyreticAnalgesicsDiseaseHuman epidermal growth factor receptor
The invention belongs to the field of medicine preparations, and relates to an injection preparation of a monoclonal antibody, in particular to an injection preparation of an EGFR (Epidermal Growth Factor Receptor) monoclonal antibody. The invention also relates to the application of the injection preparation for preparing medicines capable of preventing and / or treating diseases (including diseases which relate to tumor and / or tumor metastasis and angiogenesis and nonspecific inflammation) which relate to EGFR activity imbalance or disorder. The injection preparation of the EGFR monoclonal antibody presents good stability in experiments including shaking out, 25-40 DEG C high-temperature acceleration experiments, 2-8 DEG C long-term storage stability and the like, and has a good application prospect.
Owner:SHANGHAI JMT BIO INC
Preparation method of novel cytokine fusion protein IP10 single-chain antibody
InactiveCN103451218BEnhance targeted killing activityImprove targetingMicroorganism based processesIn-vivo testing preparationsEscherichia coliSide effect
Owner:卢小玲 +1
Humanised antibodies to epidermal growth factor receptor
The present invention provides a humanised form of the antibody 340 obtainable from the cell line deposited with the ECACC under accession number 97021428. Such antibodies have been found to have an increased ability to kill cells compared to the murine antibody 340. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular in the treatment of cancer.
Owner:SCANCELL
Anti-epidermal growth factor receptor antibodies and uses thereof
InactiveUS8653244B2High affinityHigh binding activityAnimal cellsSugar derivativesHuman epidermal growth factor receptorEpidermal Growth Factor Receptor Antibody
The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10−10 mol / L) and are able to inhibit the growth and migration of tumor cells. The present invention also discloses the preparation methods and uses of the antibodies.
Owner:GUANGZHOU YUNYUAN BIOTECH
Kit and method for detecting K-RAS (K-rat sarcoma) gene polymorphism by pyrophosphoric acid sequencing method
InactiveCN102796815AQuick analysisAccurate analysisMicrobiological testing/measurementAntiendomysial antibodiesExon
The invention discloses a kit for detecting the gene polymorphism of monoclonal antibody personalized medicine of an anti-epidermal growth factor receptor by a pyrophosphoric acid sequencing method and a method for detecting the gene polymorphism of the monoclonal antibody personalized medicine of the anti-epidermal growth factor receptor by the pyrophosphoric acid sequencing method. The invention particularly relates to the polymorphism of No.2 exon, No.12 codon and No. 13 codon of the K-ras (K-rat sarcoma) gene. The kit comprises the primer shown in the SEQ ID NO.3-4. The kit disclosed by the invention can be used for detecting the K-ras genic mutation exactly and quickly at high throughput, so that the safe, reasonable and effective individual administration can be realized for the pharmacy of the monoclonal antibody (such as cetuximab, nimotuzumab and panitumumab) of the anti-epidermal growth factor receptor.
Owner:周宏灏
Diagnosis of cancer by detecting auto-antibodies against EGF-receptor
ActiveUS10739346B2Immunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAutoantibodyReceptor
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor receptor (EGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an inhibitor of EGFR activity.
Owner:CELLTREND
Pharmaceutical formulation comprising Anti-egfr antibody
The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
Owner:THE GREEN CROSS CORP
Fully human Anti-epidermal growth factor receptor antibodies
ActiveUS20110280883A1MicroorganismsAntibody ingredientsEpidermal Growth Factor Receptor AntibodyEpidermal Growth Factor Receptor Overexpression
Disclosed are fully human anti-epidermal growth factor receptor (EGFR) antibodies, fragments thereof, and nucleic acid sequences encoding for the same. Further disclosed are methods of making and using the antibodies.
Owner:SAMSUNG ELECTRONICS CO LTD
Anti-egfr and anti-cd3 bispecific antibody and its application
ActiveCN106632681BConducive to biological functionsConducive to biological functionHybrid immunoglobulinsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseaseAntigen
The present invention relates to the field of biotechnology, in particular to an anti-EGFR and anti-CD3 bispecific antibody and its application. The bispecific antibody of the present invention can specifically bind to tumor cell surface antigen epidermal growth factor receptor EGFR and immune cell surface antigen differentiation Cluster 3 is the CD3 molecule; wherein the single-chain antibody ScFv of the anti-CD3 antibody is located at the C-terminal of the constant region of the anti-EGFR antibody. The invention also provides the preparation method and clinical application of the bispecific antibody. The bispecific antibody of the present invention has high affinity and is used for treating tumor diseases caused by high or abnormal expression of EGFR and other diseases caused by overexpression of EGFR.
Owner:BEIJING DONGFANG BIOTECH +1
Kit for detecting B-raf gene polymorphism by pyro-sequencing method and method
ActiveCN102876784BQuick analysisAccurate analysisMicrobiological testing/measurementB-RAF Gene MutationMonoclonal antibody
The invention discloses a kit for detecting B-raf gene polymorphism by a pyro-sequencing method and a method. By the kit, the B-raf gene rs113488022(V600E) single nucleotide polymorphism is detected. The kit comprises primers which are shown as SEQ ID NO.2-4. By the kit, the accurate, quick and high-throughout detection of B-raf gene mutation can be realized, so that the safe, reasonable and effective individual administration of a monoclonal antibody (such as cetuximab) of an anti-epidermal growth factor receptor, melanin inhibitor Zelboraf and the like can be realized.
Owner:CENT SOUTH UNIV
Antibody, and coding gene and application thereof
InactiveCN101875695BHigh binding activityHigh affinityFungiBacteriaHumanized antibodyChimeric antibody
The invention discloses an antibody, and a coding gene and application thereof. An amino acid sequence of a heavy chain variable region of the antibody is shown in the sequence 2 in a sequence table, while the amino acid sequence of a light chain is shown in the sequence 3 in the sequence table. Experimental results prove that the antibody of the invention has high binding activity (affinity is 2.7*10-8 mol / L) and high tumor cell growth and migration suppression capacity; and the affinity of an anti-epidermal growth factor receptor (EGFR) human-mouse chimeric antibody Cetuximab in foreign markets is 1.1*10-9 M. The humanized antibody of the invention can be better bound with an EGFR so as to ensure anti-tumor effect thereof. An anti-body preparation method of the invention has the advantage of simultaneously expressing the light chain and the heavy chain variable region. After all, the antibody and the preparation method thereof have vast application prospect in the field of the prevention and / or treatment of tumors.
Owner:INST OF BIOENG ACAD OF MILITARY MEDICAL SCI OF THE CHINESE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com